Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia

Background: Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous disease characterized by variable clinical outcomes. The introduction of targeted therapies, particularly the BCL-2 inhibitor venetoclax, has significantly improved treatment outcomes in patients with relapsed/refractory...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Asli Odabasi Giden, Duzgun Ozatli, Mehmet Ali Erkurt, Abdullah Karakus, Gulden Sincan, Fehmi Hindilerden, Yusuf Bilen, Ugur Hatipoglu, Gulsum Akgun Cagliyan, Tuba Hacibekiroglu, Sinan Demircioglu, Didar Yanardag Acik, Cengiz Demir, Yavuz Katircilar, Anil Tombak, Seda Yilmaz, Irfan Kuku, Fuat Erdem, Asli Yuksel Ozturkmen, Mehmet Sinan Dal, Semih Basci, Serdal Korkmaz, Turgay Ulas, Fevzi Altuntas
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-05-01
Edice:	Hemato
Témata:	chronic lymphocytic leukemia venetoclax relapsed/refractory real-world data BCL-2 inhibitor tumor lysis syndrome
On-line přístup:	https://www.mdpi.com/2673-6357/7/2/16
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!